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Background: A potential new treatment in smoking cessation and relapse prevention is nicotine vaccination which
is based on active immunization against the nicotine molecule. This immunization will elicit the immune system to
produce nicotine-specific antibodies that sequester nicotine in the blood stream, after inhaling tobacco products.
The resulting antibody-antigen is too large to cross the blood–brain barrier and is therefore postulated to attenuate
the rewarding effect of nicotine by preventing the latter from reaching its receptors in the brain and causing the
release of dopamine. The aim of this paper is to describe the design of a phase IIb, multi-center, double blind,
randomized, placebo controlled trial to assess the efficacy of the nicotine vaccine NicVAXW co-administered with
varenicline (ChampixW) and intensive counseling as an aid in smoking cessation and relapse prevention.
Methods/design: Two centers will include a total of 600 smokers who are motivated to quit smoking. At week −2
these smokers will be randomized, in a 1:1 ratio, to either 6 injections of NicVAXW or placebo, both co-administered
with 12-weeks of varenicline treatment, starting at week 0. The target quit day will be set after 7 days of varenicline
treatment at week 1. Smokers will be followed up for 54 weeks. The primary outcome is defined as biochemically
validated prolonged smoking abstinence from week 9 to 52. Secondary outcomes include safety, immunogenicity,
smoking abstinence from week 37 to 52, abstinence from week 9 to 24, abstinence in the subset of subjects with
the highest antibody response, and lapse/relapse rate.
Discussion: This is the first study to assess the efficacy of a nicotine conjugate vaccine in combination with an
evidence-based smoking cessation pharmacotherapy (varenicline) to quit smoking. Although NicVAXW is primarily
designed as an aid to smoking cessation, our study is designed to explore its potential to maintain abstinence and
prevent relapse. The results of this trial will give a unique insight in the potential of nicotine vaccination for relapse
prevention.
Trial registration: ClinicalTrials.gov: (NCT00995033)
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Tobacco use is the leading preventable cause of death in
the world. Currently, about 1 billion people smoke of
which eventually half will die from smoking-related dis-
eases [1]. Worldwide, approximately 6 million people die
from smoking each year, including more than 600,000
non-smokers who die from secondhand smoke [1]. Al-
though smokers are generally aware of the health conse-
quences of smoking they have major difficulties to stop
smoking [2]. Without the use of effective therapies, less
than 5% of the smokers are able to stay abstinent for
one year after a quit attempt [3].
Nicotine is responsible for the addictive mechanism
of tobacco use and the difficulties that smokers en-
counter when trying to quit smoking and remain ab-
stinent. After inhalation of cigarette smoke, nicotine
almost immediately travels to the blood stream and
crosses the blood–brain barrier within 10 to 20 seconds
[4]. At this point the nicotine molecule acts on several
neurotransmitter systems where it activates α4β2 nico-
tinic acetylcholine receptors and the dopamine reward
system responsible for the reinforcing and addictive
effects of nicotine [5].
Pharmacotherapy treatment for smoking cessation fo-
cuses on minimizing the nicotine withdrawal effects by
substitution of the nicotine reward effects or by attenu-
ating the reinforcing effects of tobacco [6,7]. Currently
available therapies such as nicotine replacement therapy
(NRT), psychotropic drugs, and partial nicotine acetyl-
choline agonists, in combination with behavioral sup-
port, can increase abstinence rates to a maximum of 20
to 25% after one year [6,8-10]. NRT reduces withdrawal
by replacement of nicotine, which might result from
abrupt cessation of nicotine use [6] while psychotropic
drugs, such as bupropion and nortriptyline cause a
blockade of neuronal re-uptake of several neurotrans-
mitters like norepinephrine, serotonine, and dopamine
[8]. Blockage of this “biology of nicotine addiction” will
reduce the reinforcing effect of nicotine and withdrawal
symptoms [8]. A more recent developed treatment strat-
egy is the use of partial nicotine acetylcholine agonists
like varenicline and cytisine, which stimulate the release
of sufficient dopamine to reduce craving and withdrawal
while simultaneously acting as a partial antagonist by
blocking the binding and consequent reinforcing effects
of inhaled nicotine [11,12].
Since the majority of smokers who attempt to quit still
fail to achieve long-term abstinence, and most smokers
relapse in the first 8 days, the need for better cessation
approaches is of major importance [3]. A potential new
treatment approach in smoking cessation and relapse
prevention is nicotine vaccination, in which smokers
who want to quit smoking receive multiple injections of
a nicotine conjugate vaccine.Nicotine vaccination: mechanism of action
Nicotine vaccination is a new therapy which is based on
active immunization against the, otherwise, non-im-
munogenic, nicotine molecule. For this purpose, the
small nicotine molecule is conjugated to a much larger
carrier protein to induce and activate the immune sys-
tem to produce highly specific nicotine antibodies [13].
These antibodies sequester nicotine in the blood stream,
after inhaling tobacco products, and the resulting
antigen-antibody molecule becomes too large to cross
the blood–brain barrier [14]. By preventing large
amounts of nicotine reaching the central nervous sys-
tem, nicotine vaccination is believed to attenuate the
rewarding effect of nicotine [15].
The nicotine conjugate vaccine NicVAXW, developed by
Nabi Biopharmaceuticals, was initially developed as an aid
in smoking cessation. For this purpose, multiple injections
are administered prior to the planned quit date resulting
in a gradual increase in anti-nicotine antibodies which
helps smokers in gradually reducing the number of cigar-
ettes and eventually achieve complete abstinence [16].
Nicotine vaccines could also be used to prevent relapse.
Hence, vaccinated ex-smokers who lapse (i.e., take a puff
of a cigarette, have a positive smoking status for 1 week
after a period of abstinence) are expected to experience
diminished reward from nicotine inhalation which could
prevent a full blown relapse (i.e., a positive smoking status
for at least 2 weeks after a period of abstinence) [17]. The
effects of a brief exposure to a positive stimuli such as sec-
ond hand smoke may also be blunted.
Nicotine vaccination: safety
Three phase I/II clinical trials with NicVAXW have been
published so far. Two of these studies were designed to
evaluate the immunogenicity and safety [18,19], while
another study was especially designed to demonstrate
the proof of concept to determine the relationship be-
tween immunogenicity and smoking cessation outcomes
[16]. Regarding the reported safety data, participants
commonly reported local reactions at the injection site
like ‘ache’ and ‘tenderness’. The reported systemic reac-
tions were mostly mild to moderate of intensity and
included symptoms of general discomfort/malaise, myal-
gia, and headache [16]. There was no significant differ-
ence in local and systemic reactions between the placebo
group and the NicVAXW treatment group [16]. Of all
reported safety data, there was only one serious adverse
event (anaphylactic reaction) in a subject with a history
of allergic reactions that was considered by the investiga-
tor to be treatment-related [16].
Nicotine vaccination: immunogenicity
Immunogenicity has been shown to be dose-related. Add-
itional injections and higher vaccine doses have been
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higher antibody titers [18]. These antibody titers typically
peak following the final injection when 4 or 5 vaccinations
are administered [16].The peak geometric mean antibody
concentration reported in response to the nicotine conju-
gate vaccine NicVAXW was 45 μg/ml in the subgroup who
received 5 injections with 400 μg of NicVAXW [16]. Previ-
ous data reported no difference in antibody response be-
tween smokers and non-smokers [19].
Nicotine vaccination: efficacy
Currently, only one study has been published to evaluate
the relationship between smoking cessation outcomes
and immunogenicity in smokers treated with 4 or 5
injections of NicVAXW in different dose schedules [16].
A subgroup of the top 30% antibody responders were
significantly more likely than the placebo group to
achieve 8 weeks of continuous abstinence from weeks 19
through 26 (24.5% vs. 12.0%, odds ratio (OR) = 2.69, 95%
confidence interval (CI) = 1.14–6.37) and weeks 19
through 52 (19.7% vs. 10.0%, OR = 2.64, 95%CI = 1.03–
6.79). The target quit day was dependent on the dose
regimen, which was either week 5 (for 5 injections
schedule) or week 7 (for 4 injections schedule). Smokers
who received the 5 injection schedule with 400 μg
NicVAXW dose elicited the highest antibody response,
which resulted in significantly higher abstinence rates
than placebo [16]. In vaccinated smokers who failed to
quit smoking, the authors observed a statistically signifi-
cant reduction in daily cigarette consumption between
the top 30% antibody responders and the placebo group
in weeks 19–52; the median reduction in cigarette con-
sumption between both groups was 4.6 cigarettes a day
[16]. There were no differences in withdrawal symptoms
and no evidence for compensatory smoking in those
smokers who received injections with NicVAXW [16].
During the conduct of the current study, Nabi Bio-
pharmaceuticals announced negative results of two
phase III, randomized, placebo controlled trials on the
efficacy of NicVAXW [20]. Both trials were designed
identically and included approximately 1,000 smokers
who received a set of 6 injections of 400 μg NicVAXW or
placebo. The preliminary results of the trials showed that
the primary endpoint of 16 weeks abstinence measured
at 12 months was not met; there was no statistically dif-
ference between the NicVAXW and placebo group [20].
Nicotine vaccination: rationale for combination with
varenicline
The purpose and rationale of the proposed study is to
evaluate the efficacy of NicVAXW co-administered with
varenicline as an aid to smoking cessation, long-term ab-
stinence, and relapse prevention. Preliminary data on
NicVAXW suggest that antibody levels peak after the lastinjection, and it is therefore likely that smokers who quit
smoking have less difficulty to remain abstinent.
In the proposed study we combine NicVAXW with a
12-week treatment of varenicline to stimulate partici-
pants to stop smoking before week 12. Varenicline is
used for immediate smoking cessation by reducing with-
drawal and craving during the first 12 weeks of treat-
ment. Varenicline has proven to be superior to placebo
for smoking cessation at one year of follow-up [9].
Therefore, this phase IIb study design will be ideal to
evaluate relapse, especially because end of treatment ab-
stinence with varenicline is about 45% from weeks 9 to
12 [11]. The current trial is designed so that the anti-
nicotine antibody concentration at the end of the vareni-
cline therapy (week 12) would be high enough to de-
crease the chance of relapse, occurring 2 weeks after the
4th vaccination. It is worth noting that anti-nicotine anti-
bodies in response to NicVAXW do not cross react with
varenicline.[Nabi unpublished data]
Primary objective
The primary objective of our trial is to evaluate the effi-
cacy of 6 injections with 400 μg of the nicotine conjugate
vaccine NicVAXW or placebo co-administered with vare-
nicline for smoking cessation and relapse prevention, by
comparing biochemically validated prolonged abstinence
from week 9 to 52 in smokers who want to quit.
Secondary objectives
There are several secondary objectives which aim to
understand the benefit of NicVAXW vaccination co-
administered with varenicline for smoking cessation.
The most important secondary objectives will be
described in detail in this article (an overview of all
other secondary objectives is listed in Appendix A).
1. To evaluate the safety and immunogenicity of
NicVAXW.
2. To evaluate abstinence rates from week 37–52
3. To evaluate abstinence rates from week 9–24
4. Abstinence from week 9–52, week 9–24 and 37–52
in the subset of NicVAX subjects with the high
antibody responses.
5. To evaluate lapse and relapse rates from week 12–52.
6. To evaluate withdrawal symptoms using the
Minnesota Nicotine Withdrawal Scale (MNWS).
7. To evaluate nicotine dependency measured by the
Fagerström Test for Nicotine Dependence (FTND).
8. To evaluate cigarette consumption.
Ethical approval
The Dutch Central Committee on Research Involving
Human Participants approved the study protocol
(NL25046.000.08).
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This trial is registered at ClinicalTrials.gov (NCT00995033).Methods/design
Study design
In this phase IIb trial a total of 600 participants will be
randomized in a 1:1 ratio to one of the 2 treatment
groups, receiving either 400 μg NicVAXW or matching
placebo, both combined with open-label varenicline and
intensive counseling (see Figure 1). After a 2-week
screening period, in which the participant will be medic-
ally approved, the follow-up for each participant is
54 weeks. All participants will receive open-label vareni-
cline starting at week 0 until week 12, together with a
total of 6 injections in weeks −2, 2, 6, 10, 14, and 24.
The target quit date will be set 1 week after starting the
use of varenicline (3 weeks after randomization). Several
quit re-challenges, where continuing smokers plan a
new quit date, will be implemented at week 12, 16, and
26 for all participants who are not able to quit smoking
successfully, corresponding to predicted elevations of
anti-nicotine Ab levels occurring 2 weeks after the 4th,
5th, and 6th vaccinations.
During follow-up, a total of 23 standardized behavioral
counseling sessions based on motivational interviewing
will be provided at the study sites (16 times) or via tele-
phone (7 times). These counseling sessions aim to sup-
port participants in their quit attempt and are
standardized to include the common elements of prac-
tical counseling (e.g., problem solving and skills train-
ing). Clinical and telephone counseling sessions will
have a duration of approximately 10 minutes and will be
performed by trained research nurses who are also re-
sponsible for the administration of the investigational
product during the injection visits.Setting
This multicenter trial is coordinated by the CAPRHI
School for Public Health and Primary Care andR TQD
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Figure 1 Study design overview.conducted at the Maastricht University Medical Centre
and Slotervaart Hospital Amsterdam, the Netherlands.
Study population
Smokers for the trial will be recruited through local
media advertisements in the surrounding areas of Maas-
tricht and Amsterdam and screened for eligibility on the
telephone. Eligible participants will be sent written
informed consent about the trial based on the principles
of proper consenting. Major inclusion criteria will be:
male or female between 18–65 years of age, being in
good general health, smoking at least 10 cigarettes per
day, and being motivated to quit smoking. The full in-
clusion and exclusion criteria for the trial are listed in
Appendix B.
Randomization and blinding
Eligible smokers will be randomly assigned to either the
active nicotine vaccine group or the placebo group by
the use of an Interactive Web Response System (IWRS).
IWRS is based on a permuted block randomization list,
where each randomization block is used by one center
only. IWRS will assign an appropriate syringe number
corresponding to the randomized treatment from the
available syringes at the study center. Under no circum-
stance will a participant be injected with the investiga-
tional product from a syringe other than the one to
which (s)he is assigned through IWRS. For proper blind-
ing, we will use identical-appearing active and placebo
vaccine syringes, which will be labeled with a unique nu-
meric code, according to a randomized labeling list. The
participants together with the involved investigators and
sponsors will be blinded to the randomization lists until
the clinical database is locked at the end of the trial.
Sample size calculation
The primary end point of this study is biochemically
validated prolonged abstinence from week 9 to week 52.
The effect of a 12-week varenicline treatment on abstin-
ence from smoking during 12 months has been shown24 52
ng term abstinence week 8-52
Abstinence week 37-52
Relapse rate week 12-52
6th
inj
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per group would provide 90% power to detect a differ-
ence in abstinence between the intervention and control
groups of at least 12% (22% in the placebo group vs. 34%
in the NicVAXW group) with a 5% Type I error rate. As
a consequence of the imputation analysis, where partici-
pants who become lost to follow-up will be included in
the analysis as a smoker according to current practice in
this field of research, the sample size is not corrected for
lost to follow-up [22].
Screening visit
After smokers have met the in- and exclusion criteria by
telephone and agree on the written informed consent,
the smokers will be invited for a screening visit. During
this first clinical visit, we will obtain written informed
consent and again review the in- and exclusion criteria.
In addition, we will collect baseline demographic vari-
ables and vital signs, together with the currently used
medications. In order to have background information
on smokers’ smoking history, we will ask each subject to
complete a tobacco use history report form with detailed
information on several topics. A physician will obtain a
medical history and a physical examination to medically
approve each smoker before randomization. Chemistry,
haematology, and urinalysis tests will be obtained for
baseline values and to medically approve the general
health status.
Primary outcome measure
Our primary efficacy outcome for this study is defined
as biochemically validated prolonged abstinence from
week 9 to 52, measured by the participants’ self-reported
smoking consumption on a weekly base and confirmed
by exhaled carbon monoxide (CO) measurements in
weeks 10, 12, 14, 18, 24, 28, 34, 40, 46, and 52, in the ab-
sence of use of NRTs during this entire period. If a CO
measurement has been collected, it should confirm the
smoking status of the participant for that week. A par-
ticipant is considered to be a validated non-smoker with
a CO level <10 ppm measured by a MicroCO (Micro
Medical ltd., United Kingdom). When a participant is a
self-reported non-smoker with an elevated CO level of
≥10 ppm, the CO-measurement supersedes the partici-
pants’ self-report and the participant is defined as a
smoker.
Secondary outcome measures
Safety
Local and systemic reactogenicity will be recorded on in-
jection days (after 30 minutes and in the evening) as well
as during the first 7 days after each injection. The par-
ticipant has to report on the presence and severity of
both local (erythema, swelling, burning, tenderness,ache, and heat) and systemic reactions (general discom-
fort/malaise, myalgia, headache, nausea, and vomiting)
together with an oral temperature measurement. Local
and systemic reactogenicity events starting 7 days post-
injection will be recorded as adverse events. For the cap-
tured systemic reactogenicity, the study site physician
will rate the relationship to the investigational product.
Adverse events (AE) and serious adverse events (SAE)
will be collected from randomization through the final
or early termination visit which are coded using the
Medical Dictionary for Regulatory Activities (MedDRA)
[23]. Assessment of AE and SAE’s relationship to the in-
vestigational product will be completed by a physician.
The use of concomitant medications will be collected
from 4 weeks prior to randomization though the entire
study period.
During all clinical visits, we will measure vital signs
(blood pressure, heart rate, respiratory frequency, and
temperature) and for injection visits both prior to the in-
jection and 25–35 minutes post injection.
Laboratory tests (haematology, chemistry, and urinaly-
sis) will be performed at the screening visit and in week
6, 12, and 52 (Table 1).
Immunogenicity
Anti-nicotine IgG antibody concentrations in partici-
pants’ sera will be measured by Enzyme-linked immuno-
sorbent assay (Elisa) at 13 time points as indicated in
Table 1.
Abstinence from week 37–52
A secondary efficacy variable for this study is the bio-
chemically confirmed 16-week abstinence at 12 months
from weeks 37 to 52. This measurement is defined as
the proportion of participants who maintained abstin-
ence from weeks 37 to 52 measured by the weekly self-
reports on smoking consumption, confirmed by exhaled
CO measured at week 40, 46, and 52, and who also do
not use NRTs during this period.
Abstinence from week 9–24
Defined as the proportion of subjects who maintained
abstinence between weeks 9 to 24, inclusive, measured
by subject self-report of smoking consumption on a
weekly basis, confirmed by exhaled CO.
Abstinence from week 9–24, week 9–52 and 37–52 in high
AB responders
Defined as biochemically confirmed 16-week abstinence
at 6 months (week 9–24), 44-week abstinence at
12 months (week 9–52) and 16-week abstinence at
12 months (week 37–52) among the high antibody
responders.
Table 1 Scheduled clinical procedures
Visits 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Study Week -4 to
-2
-2 -1 0 1 2 4 6 7 8 9 10 11 12 13 14 16 18 24 26 28 34 40 46 52/
ET
Study Day -28
to
-14
-14 -7 0 7 14 28 42 49 56 63 70 77 84 91 98 112 126 168 182 196 238 280 322 364
Visit Window (Days) ±1 ±1 ±1 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±5 ±5 ±5 ±5 ±5
Informed Consent X
Inclusion/Exclusion
Criteria
X
Medical History1 X X
Tobacco Use History1 X X
Randomize & Assign SID X
Physical Exam1 X X X
Vital signs and weight2 X X X X X X X X X X X X X X X X X X
Exhaled Carbon
Monoxide
X X X X X X X X X X X X X X X X X
Anti-Nicotine Antibody X X X X X X X X X X X X X
Laboratory tests:
Hematology,Chemistry
X X X X
Urine Pregnancy Test X3 X3 X X X X X
Urinalysis X X X X
QUIT DAY X
Quit Re-Challenge X X X
Clinic Counseling X X X X X X X X X X X X X X X X
Telephone Counseling X X X X X X X
NicVAX or Placebo X X X X X X
Varenicline X X X X X X X X X X X
Nicotine Exposure Report
Form4
X X X X X X X X X X X X X X X X X X X X X X X X X
Minnesota Nicotine
Withdrawal
Questionnaire5
X X X X X X X X
Reactogenicity
Assessment6
X X X X X X
Fagerström Test for
Nicotine Dependence
(FTND)
X X X X
Adverse Events7 X X X X X X X X X X X X X X X X X X X X X X X X
Concomitant
Medications8
X X X X X X X X X X X X X X X X X X X X X X X X X
1 Medical History, Physical Exam and Tobacco Use History must be performed prior to randomization.
2Vital signs include blood pressure, heart rate, respiration, temperature, and weight. Vital signs will be taken immediately before injection and 30 ±5 minutes post
injection.
3A negative urine pregnancy test is required for all females of childbearing potential within 3 days prior to IP injection. Females who have menstruated in the
past 12 months (even if irregularly) or are not surgically sterile are considered to be of childbearing potential.
4 The Nicotine Use Report Form will be completed weekly for entire study. Blank Nicotine Use Report Forms should be provided to the subject at each visit.
5The Minnesota Nicotine Withdrawal Questionnaire is completed weekly during weeks 12–15, weeks 26–29 and weeks 49–52.
6Reactogenicity will be collected for 7 days after each injection. Blank MNWS forms should be provided prior to each collection period.
7Adverse Events will be collected thru day 364.
8Concomitant medications will be collected thru day 364.
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Among participants with 4-week abstinence status at
12 weeks, we define relapse as at least 2 consecutive
weekly self-reports that are positive for tobacco use. A
lapse is defined as 1 weekly self-report for tobacco use
followed and preceded by 1 weekly self-report for
tobacco abstinence.
Withdrawal symptoms
Withdrawal symptoms will be measured 14 times by
using the MNWS (item scores 0=“none” to 4=“severe”),
reflecting craving for cigarettes, anger, irritability, frus-
tration, anxiety, nervousness, depression, difficulty con-
centrating, insomnia, restlessness, and increased appetite
or weight gain [24]. The MNWS will be collected at
screening, weeks 12–15, weeks 26–29, and weeks 49–52.
Nicotine dependency
Nicotine dependency will be measured by the FTND
and is administered at screening, week −2, 24, and week
52 as long as the participant continues to smoke [25].
Cigarette consumption
Information on cigarette consumption will be collected
based on the participants’ self-reports on smoking status,
in which they record their total cigarette consumption
for the prior week.
Data analysis
Data and Safety Monitoring Board (DSMB)
An independent DSMB will review all safety data avail-
able at pre-determined time points to decide on the con-
tinuation of the trial regarding the safety profile of the
investigational product. We will use SPSSW version 16.0
or higher to perform all statistical analyses.
Efficacy analysis
For our primary analysis we will compare NicVAXW ver-
sus placebo, both co-administered with varenicline, in an
intention-to-treat (ITT) analysis using a using a logistic
regression model with corresponding 95% confidence
interval, and p-value. The study has a single primary
variable, and as such, no adjustments for multiple com-
parisons will be made. All statistical tests will be two-
sided tests performed at a 0.050 level of significance.
Efficacy analysis in high AB responders
Subjects who receive NicVAX will be stratified based on
peak antibody concentration (Cmax) and based on area
under the curve. For each stratification scheme (AUC or
Cmax) subjects will be placed into two or more percent-
ile groups (50th, 33rd, 25th) based on AUC or Cmax. For
each stratification method, the abstinence rate in the top
antibody group compared with placebo will be initiallyperformed first for the top 25th percentile group. If the
initial test is positive, the hypothesis will be retested for
subsequent percentile groups (i.e., 33rd, 50th). The role of
anti-nicotine antibodies will be established if the abstin-
ent rate for the high responders (e.g. either 50th, 33rd,
25th percentile) groups is superior to placebo.
Safety analysis
For each reactogenicity type, the presence of any post-
vaccination reactogenicity, aggregated over all injections,
will be summarized and compared between the treat-
ment groups using Fisher’s exact test.
The numbers and percentages of participants experien-
cing AEs will be summarized by body system and pre-
ferred terms within a body system using the MedDRA
dictionary. Summaries of AEs will also be generated by
drug relationship and intensity. The maximum intensity
and/or relationship for an AE within a patient will be used
in these summaries. As appropriate, proportions of parti-
cipants experiencing specific adverse events will be com-
pared between the study treatments by Fisher’s exact test.
Immunogenicity analysis
Summary statistics including geometric mean concentra-
tion and corresponding 95% confidence interval, mean,
minimum, maximum, 25th and 75th percentiles, standard
deviation, and standard deviation in the log scale of anti-
body concentrations will be calculated for each time
point. The immunogenicity data will be summarized on
the ITT Analysis Set only.
Withdrawal symptoms analysis
We use baseline MNWS scores as the average of the
scores over the screening and Day 0 visits. Follow-up
MNWS scores for each participant will be averaged over
non-missing weekly MNWS scores during each collection
period (from 1–4 weeks during each collection period).
Change from baseline on the average MNWS scores dur-
ing each collection period will be analyzed with weighted
analysis of covariance (weighted ANCOVA) models which
will include the treatment group and center as factors and
corresponding baseline MNWS score as a covariate. The
number of non-missing weekly MNWS scores during
each collection period (between 1 and 4 per participant)
will be used as the weight. In addition, weekly MNWS
scores collected throughout the study will be analyzed
using mixed-effects repeated measures models. The over-
all treatment effect will be presented, along with the asso-
ciated 95% confidence interval and p-value.
Nicotine dependency analysis
The baseline score is defined as the average of the scores
collected during the screening and at week −2. A partici-
pant is considered as a smoker for completion of the
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the participant has smoked cigarettes during the previ-
ous 7 days. Change from baseline in FTND at week 24
and 52 will be analyzed with similar ANCOVA
(unweighted) and mixed-effects repeated measures mod-
els as described for the MNWS scores. The repeated
measures analysis comparing NicVAXW and placebo will
be conducted for participants who are still smoking at
the time of Fagerström data collection.
Cigarette consumption analysis
Baseline cigarette consumption is defined as the average
of the screening visit and week −2.
A mixed-effects repeated measures analysis using the
change from baseline data will be provided. The overall
treatment effect will be presented, along with the asso-
ciated 95% confidence interval and p-value. Change from
baseline to week 24 and week 52, for those participants
still smoking during week 26 and week 52 respectively,
will be analyzed using ANCOVA, as described previ-
ously. The week 52 analysis will use the last available
week’s data for completers who due to visit scheduling
do not have week 52 data (e.g. week 51).
Handling drop outs and missing data
Participants who withdraw from the study will be consid-
ered smokers for the remainder of the study. In the ab-
sence of CO measurement during a planned clinical visit,
the confirmation on smoking status will be imputed
using the CO measurements of both bordering visits. An
abstinent status will only be assigned when both
bordering visits are no more than one planned clinical
visit apart and both CO measurements at these visits are
< 10 ppm (i.e., participants are not allowed to miss two
consecutive visits with CO measurements). In all other
cases, a smoking status will be assigned. The refusal by a
participant to undergo CO testing during a clinic visit
will be considered to be an elevated CO level and the
participant to be a smoker.
Any missing self-reports on smoking status will be
imputed using both of the bordering non-missing weekly
self reports. A missing self-report will be assigned an ab-
stinent status only when both bordering self-reports
have abstinent status. This imputation will only be car-
ried out if the two bordering self-reports are no more
than 4 weeks apart.
Discussion
This will be the first study to evaluate the efficacy of a
nicotine conjugate vaccine, NicVAXW, combined with var-
enicline as an aid in smoking cessation and relapse pre-
vention. In addition, this is also the first trial to combine
nicotine vaccination with an evidence-based smoking ces-
sation pharmacotherapy. Although NicVAXW is primarilydesigned as a smoking cessation aid, rather than a
pharmacotherapy to prevent relapse in smokers who
already quit, nicotine vaccination could be an ideal ther-
apy to reduce the relapse rate.
As a consequence of the pharmacokinetics of active
vaccination, it takes at least 4–5 injections with 400 μg
NicVAXW before a sufficiently high antibody concentra-
tion is acquired. Therefore, smokers who use NicVAXW
as smoking cessation therapy may gradually reduce their
cigarette consumption before quitting. This process
could take up to 16–26 weeks (5th and 6th injection) and
could be a disadvantage for smokers who want to quit in-
stantly. This concern may be reduced in the current
protocol, which includes a small molecule with a rapid
onset of action to allow for early quit attempts, prior to
the end of varenicline treatment phase. Another potential
shortcoming could be that smokers quit smoking before
sufficient antibody titers are achieved and are therefore
at increased risk to relapse into smoking. However, vare-
nicline treatment is continued until the point that anti-
body levels are expected to be adequate. One of the
advantages of nicotine vaccination is the increased treat-
ment adherence compared to other cessation therapies
due to the mode of administration, and the persistence of
antibodies after vaccinations are completed, which may
serve a role to maintain abstinence and prevent relapse.
Because nicotine-specific antibodies will not interfere
within the central nervous system, nicotine vaccination is
also likely to have no adverse events related to interfer-
ence with the central nervous system as in NRTs, antide-
pressants, and psychotropic medication.
Phase I/II trials assessing the immunogenicity of
NicVAXW concluded that continuous abstinence was
closely related to the nicotine-specific immune response,
in which the top 30% antibody responders had signifi-
cantly higher abstinence rates than the placebo group.
These results confirm the hypothesis that NicVAXW and
nicotine-specific antibodies could play a major role in
smoking cessation.
Previously published studies on NicVAXW as cessation
therapy showed some disappointing results regarding
its efficacy on the overall treatment groups. Although
NicVAXW was safe and well tolerated, preliminary
results on the primary efficacy analysis of two large
phase III studies, with a total of 2,000 participants who
received 6 injections with 400 μg NicVAXW or placebo,
showed that continuous abstinence from week 37–52
was comparable between both treatment groups. At this
point there are no published results of the secondary
outcome measures of both phase III trials. Despite the
disappointing phase III results of NicVAXW, we see a po-
tential benefit for nicotine vaccination in future cessa-
tion programs, particularly in view of the observation in
phase IIb studies that high antibody-responses correlates
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cially relevant if NicVAXW is combined with other cessa-
tion aids such as varenicline and counseling.
This phase IIb trial is especially designed as a relapse
prevention study, in which smokers who are motivated
to quit smoking will be assisted with the use of a 12-
week varenicline treatment. The study should allow us
to gain more insight in NicVAXW as combination ther-
apy and its efficacy in relapse prevention.
Appendix A. Secondary objectives
 To evaluate safety and immunogenicity,
 To evaluate long term abstinence from week 37–52,
 Abstinence from week 9–52 and week 37–52 in the
subset of NicVAX subjects with the high antibody
responses,
 To evaluate four week abstinence from week 9–12,
 To evaluate abstinence from week 37–52 for
subjects who were intolerant to varenicline or who
were non-abstinent from week 9–12,
 To evaluate point prevalence (7-day abstinence; PP)
at 12, 26 and 52 weeks,
 To evaluate relapse rate post week 12 among
subjects with 4-week Abstinence status at 12 week.
Relapse is defined as at least 2 consecutive weekly
diary entries for tobacco use.
 To evaluate abstinence from week 9–24.
 To evaluate time to first Relapse among subjects
with 4-week Abstinence status at 12 week,
 To evaluate time to first Lapse among subjects with
4-week Abstinence status at 12 week. Lapse is
defined as 1 weekly diary entry for tobacco use
followed and preceded by 1 weekly diary entry for
tobacco abstinence,
 To evaluate time between first Lapse and first
Relapse among subjects with 4-week Abstinence
status at 12 week,
 To evaluate withdrawal symptoms using Minnesota
Nicotine Withdrawal Scale, measured at screening
and during weeks 12–15, weeks 26–29, and
weeks 49–52.
 Nicotine dependency measured by the Fagerström
Test for Nicotine Dependence.
 To evaluate Cigarette consumption.
Appendix B. Inclusion and exclusion criteria
Inclusion criteria
a) Male or female, 18–65 years of age, who has
provided written, informed consent, and who, in the
opinion of the investigator, is likely to comply with
all the requirements of the study.
b)Good general health.c) Subjects must be smoking an average of at least 10
cigarettes per day during the past year and over the
month prior to the screening visit, with no period of
abstinence greater than 3 months in the past year.
d) If a female of child-bearing potential: a negative urine
pregnancy test, and be willing to use acceptable birth
control during study participation (oral, injectable,
implantable contraceptive; intrauterine device; or
barrier method with spermacide).
e) Alveolar carbon monoxide level ≥ 8 ppm.
Exclusion criteria
a) Prior exposure to NicVAXW or any other nicotine
vaccine.
b) Any known allergic reaction to any components of
the vaccine
c) Evidence or history of clinically significant allergic
reactions. (Seasonal allergies allowed.)
d) Use of systemic steroids (>10 mg of prednisone or
equivalent per day for >14 days),
immunosuppressive agents or other medications
within 30 days prior to administration of
investigational product that might interfere with an
immune response, or intention to use such
medication within 30 days before or after
subsequent investigational product doses. (The use
of inhaled steroids is allowed.)
d) Known history of cancer or cancer treatment within
60 months prior to administration of investigational
product, except for treated basal cell or squamous
cell carcinoma.
e) Known infection with HIV, or congenital or other
acquired immunodeficiency.
f ) Known history of illicit drug or alcohol abuse or
dependence (except nicotine) within 12 months
prior to administration of investigational product
and for the study duration.
g) Known history of serious psychiatric disorder within
3 months prior to administration of investigational
product.
h) Required treatment for depression within the past
12 months.
i) History or current psychosis or bipolar disorder.
j) Current use of antidepressants, antipsychotics,
mood stabilizers, naltrexone.
k) Clinically significant cardiovascular disease within
the past 6 months. Examples of clinically significant
cardiovascular disease would include the following:
myocardial infarction, coronary artery bypass graft
(CABG), percutaneous transluminal coronary
angioplasty (PTCA), unstable angina, serious
arrhythmia, or clinically significant ECG conduction
abnormalities.
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m)Serious or unstable disease within the past
6 months, such as:
Uncontrolled hypertension.
Severe chronic obstructive pulmonary disease.
SGOT (AST) of SGPT (ALT) greater than 150%
ULN or total bilirubin greater than 110% ULN.
Elevated serum creatinine.
Other clinically significant laboratory abnormality.
n) Body mass index >38 [calculated as weight (kg)/
height2 (m)]
o) Known history of any condition or factor judged by
the investigator to preclude participation in the
study or which might hinder compliance.
p) Use of any smoking cessation treatment, such as
over the counter or prescription nicotine
replacement therapy (NRT), varenicline, bupropion,
clonidine, nortryptyline, mecamylamine within
30 days of the first administration of investigational
product, or intention to participate in any other
nicotine-related modification strategy outside the
scope of this protocol.
q) Intolerance to varenicline.
r) Use of tobacco products other than cigarettes,
including pipe tobacco, cigars, snuff, and chew, or
marijuana use within the past month and not
agreeing to abstain from use of these products
during study participation.
s) Use of Botox injections within 30 days prior to
administration of investigational product and for the
duration of the study.
t) Use of any investigational vaccine 30 days prior to
each administration of study product (licensed
vaccines may be administered at any time with the
exception of one week prior to and one week after
administration of investigational product).
u) Previous serious or unexpected adverse reaction to a
vaccine, including Guillain-Barré syndrome.
v) Anticipated inability to fulfill all visits and
examination procedures throughout the study
period (approximately 54 weeks).
w) Receipt of an Investigational New Drug/Device
30 days prior to (or 5 half-lives, whichever is longer)
administration of investigational product and for the
duration of the study.
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